A new study of 13,131 hematopoietic cell transplant (HCT) recipients whose outcomes were reported to the CIBMTR (Center for International Blood and Marrow Transplant Research) has validated the prognostic value of the Disease Risk Index (DRI). The DRI stratifies allogeneic transplant patients into four risk groups (low, intermediate, high, very high), and in this study, two-year survival in these groups was 64%, 51%, 34%, and 24%, respectively (p<0.0001). DRI score was the strongest prognostic factor regardless of age, conditioning intensity, graft source, or donor type. The researchers conclude that the DRI is a valuable and validated tool for prognostication in allogeneic HCT and for stratifying patients entering clinical trials enrolling patients across disease categories.
Large-Scale Study Validates Prognostic Value of HCT Disease Risk Index